This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • NICE has announced it does not recommend use of Op...

NICE has announced it does not recommend use of Opdivo for head and neck cancer.- BMS

Read time: 1 mins
Published:9th Jan 2021
The National Institute for Health and Care Excellence (NICE) has turned down Opdivo (nivolumab), from Bristol Myers Squibb, for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based chemotherapy. In draft guidance, NICE announced that evidence collected in the clinical trial and through its own Cancer Drugs Fund showed that people with SCCHN live longer when treated with Opdivo than with one of three possible treatments in the comparator arm. However the cost-effectiveness estimates for Opdivo were higher than those considered ‘acceptable’ by NICE for the use of NHS resources.
Condition: Head & Neck Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.